Trials / Not Yet Recruiting
Not Yet RecruitingNCT06990620
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
A Prospective, Multicenter, Single-Arm Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Ivonescimab in Unresectable, Non-Metastatic Hepatocellular Carcinoma
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic hepatocellular carcinoma (HCC), while exploring potential biomarkers associated with treatment response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | TACE+AK112 | TACE+AK112 (PD-1/VEGF bi-antibody, 20mg/kg, ivgtt, Q3W) |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2025-05-25
- Last updated
- 2025-05-25
Source: ClinicalTrials.gov record NCT06990620. Inclusion in this directory is not an endorsement.